Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001062993-21-006112
Filing Date
2021-06-30
Accepted
2021-06-30 16:31:38
Documents
1
Period of Report
2021-06-28

Document Format Files

Seq Description Document Type Size
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.html 4  
1 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES form4.xml 4 4794
  Complete submission text file 0001062993-21-006112.txt   7038
Mailing Address 230 PARK AVENUE, SUITE 2800 NEW YORK NY 10169
Business Address 230 PARK AVENUE, SUITE 2800 NEW YORK NY 10169 212-468-5800
ATP Life Science Ventures, L.P. (Reporting) CIK: 0001593440 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38944 | Film No.: 211062327

Mailing Address 230 PARK AVENUE, SUITE 2800 NEW YORK NY 10169
Business Address 230 PARK AVENUE, SUITE 2800 NEW YORK NY 10169 212-468-5800
ATP III GP, Ltd. (Reporting) CIK: 0001593453 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-38944 | Film No.: 211062326

Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Issuer) CIK: 0001744659 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations